Scientists at MIT have 1 a novel lipid nanoparticle (LNP) formulation that can cross the blood-brain barrier with unprecedented efficiency, potentially revolutionizing treatment of Alzheimer disease, Parkinson disease, and other neurological conditions.
The research, 1 in Science, builds on the mRNA delivery technology that enabled COVID-19 vaccines but solves a problem that has stymied drug developers for decades: getting therapeutics past the brain protective barrier.
The Blood-Brain Barrier Challenge
The blood-brain barrier is evolution exquisite defense system, protecting our most critical organ from toxins, pathogens, and fluctuations in blood chemistry. But this same barrier blocks 98% of potential neurological drugs from reaching their targets. For diseases like Alzheimer, where we increasingly understand the molecular culprits, the inability to deliver treatments to the brain has been a fundamental obstacle.
The Engineering Solution
The MIT team, led by Dr. Robert Langer, modified standard LNP formulations with peptides that mimic natural brain transport mechanisms. These modifications allow the nanoparticles to hitch a ride on receptor-mediated transcytosis—the same process the brain uses to import essential nutrients. "We are essentially disguising our therapeutic cargo as something the brain wants to import," explains Dr. Langer.
Key Results
The platform achieved 15-fold improvement in brain penetration over standard LNPs in mouse models, with broad distribution throughout brain tissue rather than just near blood vessels. Researchers successfully delivered mRNA, siRNA, and CRISPR components, with no signs of inflammation or barrier disruption. The system achieved therapeutic levels of protein production in neurons.
Therapeutic Applications
The platform could enable gene therapy for Huntington disease and other genetic neurological disorders, mRNA therapies to produce protective proteins in Parkinson, CRISPR-based editing to reduce toxic protein production in Alzheimer, and delivery of neurotrophic factors to protect aging neurons.
Longevity Implications
Brain aging is perhaps the most feared aspect of getting older. The ability to deliver rejuvenating therapies directly to the brain opens possibilities that were previously science fiction—from clearing accumulated waste proteins to potentially enhancing cognitive function. Moderna and BioNTech are reportedly in discussions with MIT about licensing the technology.
